An enhanced therapeutic response to PD-1 inhibitor has also been observed in genetically mutated or ALKBH5 downregulated tumor cells, highlighting the pivotal role of ALKBH5 in the regulation of immune checkpoint therapy [105]. Here, ALKBH5 is linked to neoplasm.